The Human Cancer PrimaCell™ 13: Pancreatic Tumor Cells is for rapid (7-10 days) isolation and growth of human pancreatic tumor cells from human pancreatic tumor tissues. This system features an optimal condition of tissue dissociation system, Cancer OptiTDS™ that yields 6-8 times of single cells more than most of the tissue dissociation protocols published in the literature. In addition, this system ensures a high viability of the target cells with improved gradient contained in the culture medium.

Human Cancer PrimaCell™ 13 System (Cat No. 2-96036):
Human Cancer PrimaCell™ 13: Pancreatic Tumor Cells Protocols
Human Cancer Tissue Preparation Buffer 13: Pancreatic Tumor Cells
Human Cancer OptiTDS™ 13: Tissue Dissociation System
Human Cancer PrimaCell™ 13: Pancreatic Tumor Cells Growth Medium
Human Cancer PrimaCell™ 13: Pancreatic Tumor Cells Growth Supplements with Serum (for 500 ml medium)

References:

[1] Tillotson LG, Lodestro C, Höcker M, Wiedenmann B, Newcomer CE, Reid LM. Isolation, maintenance, and characterization of human pancreatic islet tumor cells expressing vasoactive intestinal peptide. Pancreas. 2001 Jan;22(1):91-8.
[2] Ozaki K, Nagata M, Suzuki M, Fujiwara T, Miyoshi Y, Ishikawa O, Ohigashi H, Imaoka S, Takahashi E, Nakamura Y. Isolation and characterization of a novel human pancreas-specific gene, pancpin, that is down-regulated in pancreatic cancer cells. Genes Chromosomes Cancer. 1998 Jul;22(3):179-85.
[3] Paciucci R, Berrozpe G, Torà M, Navarro E, García de Herreros A, Real FX. Isolation of tissue-type plasminogen activator, cathepsin H, and non-specific cross-reacting antigen from SK-PC-1 pancreas cancer cells using subtractive hybridization. FEBS Lett. 1996 Apr 29;385(1-2):72-6.